Carboprost

Revision as of 06:26, 6 March 2019 by Jonwarren (talk | contribs) (Creation of page)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Uterotonic
  • Dosage Forms: 250 mcg/mL
  • Routes of Administration: IV, IM
  • Common Trade Names: Hemabate

Adult Dosing

Postpartum hemorrhage

  • 250 mcg IM x1
    • May repeat q15-90min for refractory bleeding
    • Max 2mg total dose

Pediatric Dosing

  • Pediatric dosing not applicable or safety has not been established in pediatric patients.

Special Populations

Pregnancy Rating

  • Avoid use in 3rd trimester
  • Possible risk of embryo-fetal toxicity

Lactation risk

  • Caution advised when breastfeeding

Renal Dosing

  • Adult: Contraindicated in acute impairment
  • Pediatric: N/a

Hepatic Dosing

  • Adult: Contraindicated in acute impairment
  • Pediatric: N/a

Contraindications

  • Allergy to class/drug
  • Hypersenstivity to prostaglandin
  • PID, acute
  • Acute renal impairment
  • Acute pulmonary disease
  • Acute hepatic disease
  • CAD
  • Caution if asthma

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: Unknown
  • Metabolism: Liver primarily, lung
  • Excretion: Urine (<1% unchanged)

Mechanism of Action

  • Stimulates smooth muscle and uterine contractions
  • Acts as synthetic prostaglandin

Comments

See Also

References

Authors:

Jonathan Warren